North Carolina-based Slate Pharmaceuticals has rounded up $5 million in its first round of funding. The developer is working on hormone replacement therapies, and the funding will be used to market an implantable testosterone pellet called Testopel, which helps men with a testosterone deficiency. The round was led by T+T Holdings and included 34 investors.
- see this report
ALSO: France's Genomic Vision, a developer of nanotechnology for DNA analysis, has raised €4 million (about $6.3 million in Series B funding). Vesalius BioCapital was joined by return backer SGAM AI. The funds will be used to expand Genomic Vision's in-house R&D programs and automation, as well as strengthen the firm's ongoing collaborative programs with partners. Release